Huntington's disease: Current and future therapeutic prospects

Movement Disorders

Volumn 33, Issue 7, 2018, Pages 1033-1041

  Kieburtz, Karl ^a   Reilmann, Ralf ^b   Olanow, C Warren ^c  

^a UNIVERSITY OF ROCHESTER   (United States)

^b George Huntington Institute   (Germany)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Huntington's Disease; Therapy

Indexed keywords

COMPLEMENTARY DNA; DIMEBON; TETRABENAZINE;

CELL GROWTH; DISEASE COURSE; DOPAMINE UPTAKE; EMBRYONIC STEM CELL; GENE DELIVERY SYSTEM; GENE EDITING; GENE THERAPY; HUMAN; HUNTINGTON CHOREA; INDUCED PLURIPOTENT STEM CELL; INVOLUNTARY MOVEMENT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY; ANIMAL; CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; HUNTINGTON DISEASE; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 85052083963     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.27363     Document Type: Review

References (93)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3.
3. Hersch SM, Schiffito G, Oakes D, et al. The CREST-E study of creatine for Huntington disease. A randomized controlled trial. Neurology 2017;89:1-8.
4. McGarry A, McDermott M, Kieburtz K, et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 2017;88:152-159.
5. Huntington Study Group DOMINO Investigators. A futility study of minocycline in Huntington's disease. Mov Disord 2010:25(12):2219-2224.
6. Bachurin SO, Shelkovnikova TA, Ustyugov AA, et al. Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice. Neurotox Res 2012;22:33-42.
7. Kieburtz K, McDermott MP, Voss TS, et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol 2010;67:154-160.
8. HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol 2013;70:25-33.
9. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
10. Huntington Study Group; Frank S, Testa CM, Stamler D, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA 2016;316:40-50.
11. Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. J Clin Mov Disord 2017 [Epub ahead of print].
12. Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Tetrabenazine versus deutetrabenazine for Huntington's disease: twins or distant cousins? Mov Disord Clin Pract 2017;4:582-585.
13. Reilmann R. Deutetrabenazine—not a revolution but welcome evolution for treating chorea in Huntington disease. JAMA Neurol. 2016;73:1404-1406.
14. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 2017;174:476-484
15. O'Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord 2015;30:1681-1687.
16. Huntington Study Group. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2015;14:39-47.
17. Dyhring T, Nielsen EO, Sonesson C, et al. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 2010;628:19-26.
18. Geva M, Kusko R, Soares H, et al. Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Hum Mol Genet 2016;25:3975-3987.
19. Sahlholm K, Arhem P, Fuxe K, Marcellino D. The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the sigma-1 receptor. Mol Psychiatry 2013;18:12-14.
20. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011;10:1049-1057.
21. Huntington Study Group. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord 2013;28:1407-1415.
22. Reilmann R, McGarry A, Landwehrmeyer GB, et al. Efficacy, safety, and tolerability of pridopidine in Huntington's disease (HD): results from the phase ii dose-ranging study, Pride-HD. Mov Disord 2017;32(Suppl S2):323-324.
23. Garcia-Miralles M, Hong X, Tan LJ, et al. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep 2016;6:31652.
24. Reilmann R, Tabrizi SJ, Leavitt BR, et al. Design of the LEGATO-HD study: A multinational, randomized, double-blind, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of laquinimod (0.5, 1.0 and 1.5 mg/day) as treatment in patients with Huntington's disease. Mov Disord 2015;30 (Suppl 1):537.
25. LaGanke C, Samkoff L, Edwards K, et al. Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial. Neurol Neuroimmunol Neuroinflamm 2017; 4:e367.
26. Southwell AL, Franciosi S, Villanueva EB, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis 2015;76:46-56.
27. Gines S, Seong IS, Fossale E, et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 2003;12:497-508.
28. Sugars KL, Brown R, Cook LJ, Swartz J, Rubinsztein DC. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J Biol Chem 2004;279:4988-4999.
29. Padovan-Neto FE, Sammut S, Chakroborty S, et al. Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways. J Neurosci 2015;35:5781-5791.
30. Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR. Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation. J Pharmacol Exp Ther 2009;328:785-795.
31. Threlfell S, West AR. Review: modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition. Basal Ganglia 2013;3:137-146.
32. Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 2010;5:e13417.
33. Chabrier PE, Auguet M. Pharmacological properties of BN82451: a novel multitargeting neuroprotective agent. CNS Drug Rev 2007;13:317-332.
34. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem 2003;86:267-272.
35. Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002;8:143-149.
36. Van Raamsdonk JM, Pearson J, Bailey CD, et al. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 2005;95:210-220.
37. Bailey CD, Johnson GV. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging 2006;27:871-879.
38. Prundean A, Youssov K, Humbert S, Bonneau D, Verny C. A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease. Mov Disord 2015;30:288-289.
39. Pallos J, Bodai L, Lukacsovich T, et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 2008;17:3767-3775.
40. Smith MR, Syed A, Lukacsovich T, et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. Hum Mol Genet 2014;23:2995-3007.
41. Jeong H, Cohen DE, Cui L, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 2011;18:159-65.
42. Jiang M, Wang J, Fu J, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 2011;18:153-158.
43. La Spada AR. Finding a sirtuin truth in Huntington's disease. Nat Med 2012;18:24-26.
44. Sussmuth SD, Haider S, Landwehrmeyer GB, et al. An exploratory double blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease. Br J Clin Pharmacol 2015;79(3):465-476.
45. Reilmann R, Squitieri F, Priller J, et al. Safety and tolerability of selisistat for the treatment of Huntington's disease: results from a randomized, double-blind, placebo-controlled phase II trial. Neurology 2014,82(Suppl 10):S47.004.
46. Reilmann R, Rouzade-Dominguez ML, Saft C, et al. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Mov Disord 2015;30:427-431.
47. Rosser A, Svendsen CN. Stem cells for cell replacement therapy: A therapeutic strategy for HD? Mov Disord 2014;29:1446-1454.
48. Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, Nauert GM, Sanberg PR, Kordower JH, Saporta S, Isacson O. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci U S A 2000;97:13877-13882.
49. Cicchetti F, Lacroix S, Cisbani G, et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol. 2014;76:31-42.
50. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504-506.
51. Schapira AH, Olanow CW, Greenamyre JT, Bezard E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 2014;384:545-555.
52. Stanek LM, Yang W, Angus S, et al. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. J Huntingtons Dis 2013; 2:217-228.
53. Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012;74:1031-1044.
54. Miniarikova J, Zanella I, Huseinovic A, et al. Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington's disease. Mol Ther Nucleic Acids 2016;7:e297.
55. Boudreau RL, McBride JL, Martins I, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 2009;17:1053-1063.
56. McBride JL, Pitzer MR, Boudreau RL, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther 2011;19:2152-2162.
57. Aronin N, Difiglia M. Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord 2014;29:1455-1461.
58. Garriga-Canut M, Agustín-Pavón C, Herrmann F, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 2012;109:E3136-F3145.
59. Olanow CW, Bartus RT, Baumann T, et al. Gene delivery of AAV2-neurturin to putamen and substantia nigra in Parkinson's disease: a double-blind, randomized, controlled trial. Ann Neurol 2015;78:248-257.
60. Olanow CW, Goetz CG, Kordower JH, et al. A double blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
61. Penney JB Jr, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5:93-99.
62. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
63. Schobel SA, Palermo G, Auinger P, et al; for the TRACK-HD, COHORT, CARE-HD, and 2CARE HSG investigators. Motor, cognitive, and functional decline form a single progressive factor in Huntington disease. Neurology 2017;89(24):2495-2502.
64. Elm JJ; NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord 2012;27:1513-1521.
65. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419-31
66. Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014;10:204-216.
67. Bechtel N, Scahill RI, Rosas HD, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010;75:2150-2160.
68. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12:637-649.
69. Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington's disease based on natural history. Mov Disord 2014;29:1335-1341.
70. Scahill RI, Hobbs NZ, Say MJ, et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp 2013;34:519-529.
71. Delmaire C, Dumas EM, Sharman MA, et al. The structural correlates of functional deficits in early Huntington's disease. Hum Brain Mapp 2013;34:2141-2153.
72. Reilmann R, Rouzade-Dominguez ML, Saft C, et al. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Mov Disord 2015;30:427-431.
73. Wild EJ, Boggio R, Langbehn D, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest 2015;125:1979-1986.
74. Southwell AL, Smith SE, Davis TR, et al. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep 2015; 5:12166.
75. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
76. Paulsen JS, Long JD, Johnson HJ, et al. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 2014 6:78.
77. Paulsen JS, Long JD, Ross CA, et al. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Lancet Neurol 2014;13:1193-1201.
78. Killoran A, Biglan K, Julian-Baros E, Yoritomoto N, Ross CA. Baseline characteristics of the PREQUEL cohort: an interventional trial in pre-manifest Huntington's disease. 2012:185.
79. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 2013;368:1169-1171.
80. Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest 2011;121:476-483.
81. Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 2012;27:31-41.
82. Sampaio C, Borowsky B, Reilmann R. Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches. Mov Disord 2014;29:1419-1428.
83. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506.
84. Bates GP, Gonitel R. Mouse models of triplet repeat diseases. Mol Biotechnol 2006;32:147-58.
85. von Horsten S, Schmitt I, Nguyen HP, et al. Transgenic rat model of Huntington's disease. Hum Mol Genet 2003;12:617-624.
86. Yu-Taeger L, Petrasch-Parwez E, Osmand AP, et al. A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. J Neurosci 2012;32:15426-15438.
87. Morton AJ, Howland DS. Large genetic animal models of Huntington's disease. J Huntingtons Dis 2013;2:3-19.
88. acobsen JC, Bawden CS, Rudiger SR, et al. An ovine transgenic Huntington's disease model. Hum Mol Genet 2010;19:1873-1882.
89. Baxa M, Hruska-Plochan M, Juhas S, et al. A transgenic minipig model of Huntington's disease. J Huntingtons Dis 2013;2:47-68.
90. Schramke S, Schuldenzucker V, Schubert R, et al. Behavioral phenotyping of minipigs transgenic for the Huntington gene. J Neurosci Methods 2016;265:34-45.
91. Schubert R, Frank F, Nagelmann N, et al. Neuroimaging of a minipig model of Huntington's disease: feasibility of volumetric, diffusion-weighted and spectroscopic assessments. J Neurosci Methods 2016;265:46-55.
92. Howland DS, Munoz-Sanjuan I. Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease. Mov Disord 2014;29:1397-403.
93. Stocchi F, Olanow CW. Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Mov Disord 2013;28:3-7.